IMV (IMV) Stock Price, News & Analysis

Company Overview

IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.49 to $0.91
• 52-Week Range: N/A
• Volume: 44,800 shs
• Average Volume: 233,607 shs
• Market Capitalization: $9.63 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IMV Stock Analysis - Frequently Asked Questions

How were IMV's earnings last quarter?

IMV Inc. (NASDAQ:IMV) posted its quarterly earnings data on Thursday, November, 11th. The company reported ($1.30) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.30). The business earned $0.04 million during the quarter. IMV had a negative net margin of 11,547.42% and a negative trailing twelve-month return on equity of 12,695.41%.

When did IMV's stock split?

Shares of IMV reverse split on the morning of Tuesday, December 13th 2022. The 1-10 reverse split was announced on Tuesday, December 13th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 13th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of IMV own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IMV investors own include Pfizer (PFE), Nokia (NOK), NIO (NIO), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), VBI Vaccines (VBIV) and Sorrento Therapeutics (SRNE).

Company Calendar

• Last Earnings: 11/11/2021
• Today: 6/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:IMV
• CIK: 1734768
• Web: imv-inc.com
• Phone: (902) 492-1819
• Fax: N/A
• Employees: 97
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($4.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$37.99 million
• Net Margins: -11,547.42%
• Pretax Margin: -11,547.42%
• Return on Equity: -12,695.41%
• Return on Assets: -104.84%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.93
• Quick Ratio: 2.93

Sales & Book Value

• Annual Sales: $330 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.69) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 11,712,000
• Free Float: 11,673,000
• Market Cap: $9.63 million
• Optionable: Optionable
• Beta: 0.95